391 related articles for article (PubMed ID: 15837818)
21. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
22. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
Kanai Y; Hara T; Imai A; Sakakibara A
J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
[TBL] [Abstract][Full Text] [Related]
23. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
24. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
Leánez S; Hervera A; Pol O
Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
[TBL] [Abstract][Full Text] [Related]
25. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
26. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat.
Mills C; McMackin M; Jaffe R; Yu J; Zininberg E; Slee D; Gogas K; Bradbury M
Neuroscience; 2008 Sep; 156(1):165-74. PubMed ID: 18706981
[TBL] [Abstract][Full Text] [Related]
27. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain.
Costa B; Trovato AE; Comelli F; Giagnoni G; Colleoni M
Eur J Pharmacol; 2007 Feb; 556(1-3):75-83. PubMed ID: 17157290
[TBL] [Abstract][Full Text] [Related]
28. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].
La Rana G; Russo R; Campolongo P; Bortolato M; Mangieri RA; Cuomo V; Iacono A; Raso GM; Meli R; Piomelli D; Calignano A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1365-71. PubMed ID: 16510698
[TBL] [Abstract][Full Text] [Related]
29. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
30. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
31. Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats.
McGaraughty S; Chu KL; Brown BS; Zhu CZ; Zhong C; Joshi SK; Honore P; Faltynek CR; Jarvis MF
J Neurophysiol; 2008 Dec; 100(6):3158-66. PubMed ID: 18829846
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses.
Petrillo P; Angelici O; Bingham S; Ficalora G; Garnier M; Zaratin PF; Petrone G; Pozzi O; Sbacchi M; Stean TO; Upton N; Dondio GM; Scheideler MA
J Pharmacol Exp Ther; 2003 Dec; 307(3):1079-89. PubMed ID: 14551288
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models.
Kohara A; Nagakura Y; Kiso T; Toya T; Watabiki T; Tamura S; Shitaka Y; Itahana H; Okada M
Eur J Pharmacol; 2007 Sep; 571(1):8-16. PubMed ID: 17597604
[TBL] [Abstract][Full Text] [Related]
34. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
Villetti G; Bergamaschi M; Bassani F; Bolzoni PT; Maiorino M; Pietra C; Rondelli I; Chamiot-Clerc P; Simonato M; Barbieri M
J Pharmacol Exp Ther; 2003 Aug; 306(2):804-14. PubMed ID: 12750440
[TBL] [Abstract][Full Text] [Related]
35. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice.
Sándor K; Bölcskei K; McDougall JJ; Schuelert N; Reglodi D; Elekes K; Petho G; Pintér E; Szolcsányi J; Helyes Z
Pain; 2009 Jan; 141(1-2):143-50. PubMed ID: 19091468
[TBL] [Abstract][Full Text] [Related]
36. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
37. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain.
Stöhr T; Krause E; Selve N
Eur J Pain; 2006 Apr; 10(3):241-9. PubMed ID: 15946870
[TBL] [Abstract][Full Text] [Related]
38. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
39. Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice.
Marabese I; de Novellis V; Palazzo E; Scafuro MA; Vita D; Rossi F; Maione S
Neuropharmacology; 2007 Feb; 52(2):253-62. PubMed ID: 17113112
[TBL] [Abstract][Full Text] [Related]
40. The analgesic effect induced by capsaicin is enhanced in inflammatory states.
Menéndez L; Lastra A; Hidalgo A; Baamonde A
Life Sci; 2004 May; 74(26):3235-44. PubMed ID: 15094324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
